Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

CagriSema shows mild-to-moderate side effects in trials
Researcher sees benefit to additional weight-loss options
Novo Nordisk plans regulatory filing for CagriSema in early 2026
June 22 (Reuters) - Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive.
The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.
The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine.
In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients.
In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group.
"Everything was in line with what we expected," Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters.
The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group.
Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. "Those patients on lower doses actually had higher weight loss reduction," she said. "We've not really seen that before because we have not had powerful treatments that have got people close to target."
CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin.
The CagriSema Phase 3 trial results "compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class," Dr. Davies said.
Eli Lilly's tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks.
Dr. Davies said it makes sense to have more options for patients, including "theoretical benefits" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said.
Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026.
"We expect to see approval maybe around the beginning of 2027," Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes.
Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. "This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects," he said.
(Reporting By Deena Beasley, Editing by Franklin Paul)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Mint

5 hours ago

• Mint

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

CagriSema shows mild-to-moderate side effects in trials Researcher sees benefit to additional weight-loss options Novo Nordisk plans regulatory filing for CagriSema in early 2026 June 22 (Reuters) - Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen. The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients. In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group. "Everything was in line with what we expected," Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters. The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group. Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. "Those patients on lower doses actually had higher weight loss reduction," she said. "We've not really seen that before because we have not had powerful treatments that have got people close to target." CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin. The CagriSema Phase 3 trial results "compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class," Dr. Davies said. Eli Lilly's tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks. Dr. Davies said it makes sense to have more options for patients, including "theoretical benefits" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said. Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026. "We expect to see approval maybe around the beginning of 2027," Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes. Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. "This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects," he said. (Reporting By Deena Beasley, Editing by Franklin Paul)

Business Standard

13 hours ago

• Business Standard

IVF players on expansion mode in smaller towns as fertility rates go down

Major in-vitro fertilisation (IVF) chains are expanding into untapped Tier 2 and 3 cities, driven by improved healthcare infrastructure, growing acceptance of fertility treatments, and rising disposable incomes in smaller urban centres. Birla Fertility and IVF, which currently operates around 30 centres in Tier 2 and 3 cities, plans to open at least 15 to 16 more centres in FY26, two-thirds of which will be in smaller towns. Nova IVF, which derives 40 per cent of its revenue from such cities, is exploring expansion in 15 locations including Haldwani, Jamnagar and Meerut. Indira IVF, the country's largest infertility chain, has also announced plans to enter over 25 Tier 3 cities by FY27. Explaining the rationale, Shobhit Agarwal, Chief Executive Officer (CEO) of Nova IVF Fertility, said, 'With one in six couples experiencing infertility in India, there is a need for fertility chains to expand to cater to couples battling infertility.' A recent United Nations Population Fund (UNFPA) report highlighted that India's total fertility rate (TFR) has fallen to 1.9 births per woman — below the replacement level of 2.1. The report echoes findings from the National Family Health Survey (NFHS)-5, which pegged India's TFR at 2.0 births per woman for 2019–21. The NFHS-5 also found the fertility rate had declined more significantly in rural areas, where it stood at 2.1 — down from 3.7 in NFHS-1 (1992–93). In urban areas, it fell to 1.6 from 2.7 in the same period. While infertility is not the sole factor behind the falling TFR, experts suggest infertility cases are expected to rise beyond Tier 1 cities, fuelled by stress-related lifestyle diseases and climate change. Industry insiders say IVF players are already witnessing increased demand for infertility treatment from Tier 2 and 3 cities. Abhishek Aggrawal, CEO of Birla Fertility and IVF, told Business Standard that more than 50 per cent of the company's annual IVF cycles are conducted in cities such as Siliguri, Varanasi and Prayagraj. 'While there is a rising segment in metros, with IVF chains receiving queries from women for procedures like egg freezing to delay parenthood, Tier 2 cities are providing an opportunity to tap less penetrated, high-potential markets,' he said. Agarwal added that many couples from Tier 2 regions find it difficult to travel to larger cities for fertility treatment, as the cost of travel, accommodation and lost wages makes the process financially burdensome. 'With expansion, we are bringing standardised fertility treatment to their home towns, with the best clinical acumen and embryologists,' he said. This model, he added, is affordable and avoids additional hassle. India currently performs around 200,000 to 250,000 IVF cycles annually, and the market is projected to grow to 400,000 cycles by 2030, with smaller cities expected to account for a substantial share of this growth. Aggrawal noted that to meet this growing demand, IVF chains are also focusing on building awareness to ensure fertility care is both accessible and better understood by those in need.

Time of India

19 hours ago

• Time of India

Fatehabad constable's infant son battles rare genetic disorder, cops across 6 dists mobilise to raise funds

Hisar: Eight-month-old Yuvansh, the son of Fatehabad police's cyber cell constable Rajesh, is battling Spinal Muscular Atrophy Type-1 (SMA), one of the rarest and most severe genetic disorders affecting infants. His survival depends on a life-saving injection costing Rs 14.5 crore, which must be procured from Switzerland. In a show of solidarity, police departments across six districts have joined hands to help raise the required amount. Rohtak additional director general of police Y Puran Kumar has written to the superintendents of police (SPs) in Rohtak, Bhiwani, and Charkhi Dadri urging officers to donate one day's salary for the cause. SPs of Kaithal (Aastha Modi) and Sirsa (Mayank Gupta) have also issued similar appeals. Policemen in Fatehabad are contributing at the local level as well. It is estimated that if officers across these districts contribute one day's salary, it could generate a significant portion of the funds required. Constable Rajesh and his wife Kiran, a clerk in the food supply department, are receiving support not only from the police but also from employees of her department. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo Public awareness campaigns and fundraising efforts have also gained traction on social media platforms. So far, around Rs 38 lakh has been collected through donations. Adampur MLA Chandraprakash has written to Haryana chief minister Nayab Singh Saini seeking financial aid for Yuvansh's treatment. Constable Rajesh has also met Hisar ADGP K K Rao in his appeal for assistance. Yuvansh was born on April 9, 2024. His parents noticed that by the time he was two months old, he was not showing normal physical development. After consulting multiple doctors and undergoing various tests, the family received confirmation of SMA on May 18, 2025. The condition was further reviewed by doctors at PGI Chandigarh, who advised urgent administration of the Zolgensma gene therapy injection — considered one of the most expensive drugs in the world. Doctors emphasised that the injection must be administered before the age of two for the best possible outcome, followed by continued treatment for at least two to three months. In a desperate appeal, constable Rajesh has reached out to several prominent personalities and institutions for help. His pleas have been directed at Prime Minister Narendra Modi, CM Nayab Saini, actors Salman Khan and Sonu Sood, transport minister Anil Vij, MP Naveen Jindal, the Tata Foundation, industrialist Gautam Adani, and the Union health ministry. The campaign to save baby Yuvansh continues to gain momentum as citizens, officials, and well-wishers across the state rally in support. MSID:: 121993767 413 |